A Life-threatening Central Nervous System-tuberculosis Inflammatory Reaction Nonresponsive to Corticosteroids and Successfully Controlled by Infliximab in a Young Patient with a Variant of Juvenile Idiopathic Arthritis
Overview
Affiliations
We report a young patient with a variant of juvenile idiopathic arthritis, who, after 4 years of infliximab treatment, developed miliary tuberculosis (TB) with central nervous system involvement (meningitis and multiple tuberculomas). After anti-TB treatment, clinical and radiologic responses were observed, but severe cerebrospinal fluid and brain inflammatory reaction, nonresponsive to corticosteroids, persisted. It was considered a life-threatening paradoxical reaction based on initial cerebrospinal fluid isolation of Mycobacterium tuberculosis fully sensitive to primary anti-TB drugs. After 4 months in the hospital, infliximab was administered considering that infliximab is a potent tumor necrosis factor α inhibiting agent that participates in the formation and preservation of granulomas and may help to modulate the exaggerated cell-mediated immune response against mycobacterial antigens. Clinical complications associated to brain inflammation resolved, and after 3 years of follow-up, the patient remains self-sufficient without neurologic sequels.
The Neuro-Ophthalmology of Tuberculosis.
Shree R, Mahesh K, Takkar A, Modi M, Goyal M, Lal V Neuroophthalmology. 2024; 48(2):73-92.
PMID: 38487360 PMC: 10936603. DOI: 10.1080/01658107.2023.2281435.
Armange L, Lacroix A, Petitgas P, Arvieux C, Piau-Couapel C, Poubeau P Eur J Clin Microbiol Infect Dis. 2023; 42(4):413-422.
PMID: 36795280 DOI: 10.1007/s10096-023-04564-2.
Patil M, Rizvi I, Garg R, Malhotra H, Kumar N, Uniyal R Acta Neurol Belg. 2022; 123(5):1869-1883.
PMID: 36306031 DOI: 10.1007/s13760-022-02123-8.
CNS TB-IRIS Following Cessation of Adalimumab in an Adolescent With Crohn's Disease.
Christian E, Johnston A Open Forum Infect Dis. 2022; 9(8):ofac367.
PMID: 35949406 PMC: 9356675. DOI: 10.1093/ofid/ofac367.
Host Directed Therapies for Tuberculous Meningitis.
Davis A, Donovan J, Bremer M, van Toorn R, Schoeman J, Dadabhoy A Wellcome Open Res. 2022; 5():292.
PMID: 35118196 PMC: 8792876. DOI: 10.12688/wellcomeopenres.16474.2.